Steward Partners Investment Advisory’s Compass Therapeutics CMPX Stock Holding History

Steward Partners Investment Advisory’s Portfolio CMPX Stock Details CMPX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4	Buy	+2	New	+$6	﹤0.01%	4636

Other funds holding CMPX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return

Steward Partners Investment Advisory's CMPX Position: Q2 2026 in Review

Steward Partners Investment Advisory opened a new position in Compass Therapeutics (CMPX) in Q2 2026: 2 shares worth $4. The stake represents ﹤0.01% of the portfolio and ranks #4636 among its holdings.

135 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

Steward Partners Investment Advisory held 2 shares of Compass Therapeutics worth $4 as of Q2 2026.
Compass Therapeutics was a new Steward Partners Investment Advisory position in Q2 2026.
Compass Therapeutics made up ﹤0.01% of Steward Partners Investment Advisory's portfolio in Q2 2026, its #4636 holding.
135 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q2 2026, filed 13 Aug 2026.